The study cohort included 66 volunteers who underwent resting-state fMRI at two time points separated by one year. Thirty-one participants were aged 16–17 years and 35 were aged 26–29 years. Twenty-nine participants reported regular cannabis use, while 37 were age-matched cannabis-naive controls. The investigators performed seed-to-voxel analyses to characterise longitudinal changes in functional connectivity across age and user-group. The source abstract did not provide full imaging parameters, seed definitions, motion correction strategies, or statistical thresholding details; those methodological specifics were not reported in the material supplied here.
The analytic framework targeted large-scale networks and their inter-regional coupling. Investigators examined year-change effects and age-by-user-group interactions to test the hypothesis that regular cannabis use would be associated with differential one-year connectivity trajectories between adolescents and adults. The study team reported results at the network and regional level rather than presenting a single global metric of connectivity.
Data indicated year-change and age-by-user-group interactions in connectivity within the salience network and the default mode network. The cohort showed divergent changes in anticorrelations between these networks and several regions, including medial prefrontal cortex, thalamus, cerebellum and juxtapositional areas. Effects were not uniform: directionality differed by both network and target region. In some cases the cannabis-use group demonstrated attenuated anticorrelations over the year interval; in others the patterns reflected reductions in positive coupling. These changes were predominantly observed in regions known to contribute to attentional control and transmodal information processing.
The study team framed these findings as evidence that maturational refinement of higher-order systems may follow altered trajectories in association with cannabis exposure. Observed network-level differences were developmentally dissociable, meaning adolescent users and adult users showed different longitudinal patterns rather than a single consistent effect across ages.
Beyond salience and default-mode interactions, the investigators reported additional main effects of user group for the executive control network and for associative striatal connectivity. Specifically, the cannabis-use group showed decreased positive connectivity within the executive control network in some regions. For associative striatal coupling the cannabis-use group showed reduced anticorrelation compared with controls. The abstract did not enumerate which precise seeds or striatal parcels produced these effects; those regionally specific methodological details were not included in the supplied source excerpt.
These main effects by user group suggest alterations that are present across ages as well as age-dependent changes. The reported pattern—decreased positive connectivity in executive control circuits combined with reduced anticorrelation in associative striatum—aligns with the broader finding that cannabis-associated connectivity differences cluster in networks supporting attention, executive function and higher-order integration.
The authors interpreted the pattern of findings to suggest that regular cannabis use may be associated with alterations in the maturational refinement of higher-order neural systems, with possible age-related differences in neurobiological sensitivity to exposure. They argued that developmental stage should be considered when characterising cannabis-related neurobiological differences and when thinking about age-dependent vulnerability to psychiatric outcomes associated with cannabis.
Limitations documented in the source: the article is a preprint and has not been peer reviewed. The abstract did not report detailed fMRI acquisition parameters, seed definitions, preprocessing steps, or the statistical thresholds used for inference; those methodological elements were therefore not available in the source material provided here. Causality cannot be established from the described longitudinal associations: the source does not report experimental manipulation, nor does it specify whether analyses accounted for potential confounders such as concurrent substance use, psychiatric history, or socioeconomic variables in the abstract.
Unanswered clinical and research questions left by the report include whether the observed connectivity differences reflect reversible effects of cannabis exposure versus persistent developmental deviations, which specific exposure characteristics (for example dose, frequency, potency or age at onset) drive the effects, and how these imaging changes relate to functional outcomes or psychiatric risk over longer follow-up. The source did not list planned regulatory milestones or peer-review timelines; those items were not reported in the provided material. Future work that the authors imply would need to address these causal and exposure-specific questions with more detailed methodology and extended follow-up.
Funding declarations in the source identified support from the MRC Clinical Trials Unit at UCL (MR/P012728/1) and UK Research and Innovation (MR/Y017560/1). The study authors included employees of Perceptive Inc.; competing interest information was reported in the source abstract.
The report ends with the practical recommendation—based on their data—that investigators and clinicians consider developmental stage when interpreting cannabis-related neurobiological differences. The material supplied does not offer clinical guidance or prescriptive recommendations for screening or treatment, and it remains preliminary pending peer review and additional methodological detail.